Gema Biotech S.A.
🇦🇷Argentina
- Country
- 🇦🇷Argentina
- Ownership
- Private
- Established
- 1998-01-01
- Employees
- 251
- Market Cap
- -
- Website
- https://www.gemabiotech.com
Clinical Trials
4
Active:0
Completed:2
Trial Phases
1 Phases
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (100.0%)Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Gema Biotech S.A.
- Target Recruit Count
- 120
- Registration Number
- NCT03404752
- Locations
- 🇦🇷
COIBA, Buenos Aires, Bs As, Argentina
Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Gema Biotech S.A.
- Target Recruit Count
- 141
- Registration Number
- NCT03403140
- Locations
- 🇦🇷
Instituto Medico CER, Bs As, Argentina
Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Gema Biotech S.A.
- Target Recruit Count
- 168
- Registration Number
- NCT03332719
- Locations
- 🇦🇷
Instituto Medico CER, Bs As, Argentina
A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Drug: Gonal-F®Drug: FOLITIME®
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Gema Biotech S.A.
- Target Recruit Count
- 106
- Registration Number
- NCT02454556
- Locations
- 🇦🇷
Halitus Instituto Médico, Buenos Aires, Caba, Argentina
News
No news found